Third Party License Fees. Ambient shall be obligated to pay all license fees and royalties, if any, with respect to any third party proprietary rights and technologies which are required for the fulfillment of its obligations under this Agreement.
Third Party License Fees. (a) GW shall remain responsible for the payment of royalty, milestone and other payment obligations, if any, due to Third Parties under any GW Technology which has been licensed to GW and is sublicensed to Novartis under this Agreement. All such payments shall be made promptly by GW in accordance with the terms of the applicable license agreement(s). In addition, in the event the Parties agree that rights to any Patent Rights issuing in the Territory from patent application *** are required to use, import, sell or otherwise Commercialize the Product in any country in the Territory, GW shall negotiate and acquire such rights through a license or otherwise at its own cost and expense, and such rights shall thereafter be deemed part of the GW Technology licensed to Novartis hereunder. *** Portions of this page have been omitted pursuant to a request for Confidential Treatment and filed separately with the Commission.
(b) Subject to the provisions of Sections 7.4(a) and 13.1(d), in the event that either Party determines that rights to intellectual property owned or Controlled by a Third Party are required to research, develop, manufacture, use, import, sell or otherwise Commercialize a Product in any country in the Territory (in addition to the GW Technology and outside the intellectual property falling under the scope of sub-Section 7.4(a)) (such Third Party intellectual property being “Relevant Third Party Rights”), it shall bring to the attention of the other Party such Relevant Third Party Patent Rights, and subject to the execution of a community of interest or joint defence agreement, provide to the other Party written notice of the basis of the determination that such a license is required and any available evidence related to such determination. GW shall have the right to determine whether any license to any such Relevant Third Party Rights is required; provided, however, that in the event that GW determines that no such license is required with respect to any given Relevant Third Party Right(s), the indemnity set forth in Section 13.1(e) shall apply with respect to such Relevant Third Party Right(s). GW shall also have the right to negotiate and acquire access to such Relevant Third Party Rights through a license or otherwise (but in each case such that the Relevant Third Party Rights are Controlled by GW and included in the licenses granted to Novartis under Section 2.1) and to add to the payments due to GW hereunder *** percent (***%) of the amounts...
Third Party License Fees. Except as expressly agreed in writing by an SIE Company, if SIE’s exercise of any of the rights granted by Publisher under this GDPA causes SIE or any Affiliate to become legally responsible for the payment of any fees, costs or expenses to any content rights holder or third party collecting payment for the use of voice, music, video, or other content, including unions, guilds, or performing rights organizations, then SIE reserves the right to offset such third party fees, costs or expenses from amounts due to Publisher under this Section 15, or, in SIE’s sole discretion, reimbursement by Publisher to SIE or the applicable Affiliate.
Third Party License Fees. The Product will require licenses to use certain third party technology. Giant & ECI are responsible for procuring such licenses from third party suppliers (e.g. Broadcom, Windriver). In conjunction with these licenses, ShoreTel shall pay a total of **** to Giant with **** paid upfront and the balance upon 1st production shipment of phones.
Third Party License Fees. To the extent the Public Health License triggers payments to Third Parties, including license fees and royalty payments, CEPI shall assume these payment obligations, and reimburse any payments made by Partner for such use.
Third Party License Fees. Until such date as Antegren, or as applicable, other Licensed Product, is Commercialized in the Territory the Parties *** of any Third Party License Fees relating thereto. The Party paying any Third Party License Fee shall invoice the other Party for its share of such Third Party License Fee within sixty (60) days after the date of payment. The Party receiving such invoice shall reimburse the other Party for its share of such Third Party License Fees within forty-five (45) days after receiving the invoice therefor. After the date when Antegren, or as applicable, other Licensed Product, is Commercialized in the Territory, Third Party License Fees shall be treated as "Other Out of Pocket Costs" under Exhibit B.
Third Party License Fees. A description of each Party's Third Party License obligations with respect to Know How or Patent Rights Controlled by such Party and to be used during the course of the collaboration is set forth on Exhibit 1.11. Until such date as an R&D Candidate becomes a Collaboration Product the Parties shall equally share in the costs of any Third Party License Fees relating to the Research and/or Development under this Agreement of each R&D Candidate subject to a Third Party License Fee obligation disclosed upon Exhibit 1.11; provided, however, that CAT shall be solely responsible for any Third Party License Fee (other than any Third Party License Fee attributable to antigens being screened as part of the Operation of the CAT Antibody Library which shall be shared equally in accordance with this Section) arising out of the Operation of the CAT Antibody Library which is in excess of [***], individually or in the aggregate. Third Party License Fees to be shared equally in accordance with this Section 5.3.5 should be charged by the relevant Party to its R&D Account. For the purposes of this Section 5.3.5, "Operation of the CAT Antibody Library" shall mean the screening of antigens against the CAT Antibody Library and the isolation of single-chain Fv fragments (and Antibodies derived therefrom) from the CAT Antibody Library.
Third Party License Fees. If Biosite or Merck is obligated to pay any amounts to one or more Third Parties in consideration for the license or other rights to any Third Party Patent Rights or Know-How, other than amounts calculated on the basis of sales of Products, such amounts shall be shared sixty percent (60%) by Biosite and forty percent (40%) by Merck.
Third Party License Fees. Organon shall be responsible for all Third Party License Fees relating to (i) the Current Product and (ii) the manufacturing process identified in Schedule 9.8, provided however that Third Party License Fees payable to [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] as set forth on Schedule 1.133 hereto shall be shared [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] percent ([CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION]%) by Pfizer and [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] percent ([CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION]%) by Organon. Unless otherwise agreed, the Parties shall share [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] percent ([CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION]%) by Pfizer and [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] percent ([CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION]%) by Organon all other Third Party License Fees relating to (x) all Products other than the Current Product, and (y) the Current Product as a result of a change to the manufacturing process identified in Schedule 9.8. With respect to Pfizer's responsibility for [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION] percent ([CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION]%) of the royalties payable by Organon to [CONFIDENTIAL INFORMATION HAS BEEN OMITTED AND FURNISHED SEPARATELY TO THE SECURITIES AND EXCHANGE COMMISSION], Organon shall send Pfizer a Calendar Quarterly invoice that shall be based on Organon's Calendar Quarterly report of Net Sales pursuant to Article 8A.4 and shall reflect the amounts due from Pfizer under this Article 9.
Third Party License Fees. (a) Schedule 4.13 lists, to the knowledge of Contributor, all third party license fees and annual maintenance fees relating to software used by Contributor at its data center facilities to run the Fairway System and the STS System which would be incurred in connection with a transfer of the Fairway System and the STS System to the Partnership if the transfer were to occur at the date of this Agreement.
(b) All fees incurred by Contributor in connection with the contribution of the Fairway System and the licensing of the STS System to the Partnership, including but not
